Rapid Dose Therapeutics's quarterly market cap
increased
from May. 2025 ($18.37 Mil) to Aug. 2025 ($18.44 Mil) and
increased
from Aug. 2025 ($18.44 Mil) to Nov. 2025 ($20.22 Mil).
Rapid Dose Therapeutics's annual market cap
increased
from Feb. 2023 ($0.04 Mil) to Feb. 2024 ($1.78 Mil) and
increased
from Feb. 2024 ($1.78 Mil) to Feb. 2025 ($23.32 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Rapid Dose Therapeutics's Enterprise Value for Today is $15.15 Mil.
Rapid Dose Therapeutics (OTCPK:RDTCF) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Rapid Dose Therapeutics Market Cap Related Terms
Rapid Dose Therapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Rapid Dose Therapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rapid Dose Therapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Rapid Dose Therapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Rapid Dose Therapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Rapid Dose Therapeutics's Market Cap for the fiscal year that ended in Feb. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rapid Dose Therapeutics (RDTCF) has a Market Cap of $10.95 Mil as of Jul. 08, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rapid Dose Therapeutics and its competitors. According to the industry distribution chart, Rapid Dose Therapeutics ranks #1193 out of 1420 companies in the Biotechnology industry, placing it in the top 84%.
Is Rapid Dose Therapeutics' Market Cap too high?
Rapid Dose Therapeutics' current Market Cap is $10.95 Mil. The Biotechnology industry median Market Cap is 121.52. Rapid Dose Therapeutics' value of $10.95 Mil is 91% below this industry median. Based on the distribution chart, Rapid Dose Therapeutics ranks #1193 out of 1420 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Rapid Dose Therapeutics has a GF Score™ of 27/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Rapid Dose Therapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Rapid Dose Therapeutics ranks #1193 out of 1420 companies for Market Cap. This places Rapid Dose Therapeutics in the lower half of its industry. The industry median Market Cap is 121.52. Rapid Dose Therapeutics' value of $10.95 Mil is 91% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 121.52, based on 1,420 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Rapid Dose Therapeutics's current Market Cap of $10.95 Mil is 91% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Rapid Dose Therapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 121.52 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rapid Dose Therapeutics's current Market Cap is $10.95 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapid Dose Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Rapid Dose Therapeutics (RDTCF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.30, compared to a current price of $0.08 — trading 73.3% below its estimated fair value. The current Market Cap is $10.95 Mil and 91% below the Biotechnology industry median of 121.52. Rapid Dose Therapeutics' overall GF Score™ is 27/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Rapid Dose Therapeutics (RDTCF), the current Market Cap is $10.95 Mil as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Rapid Dose Therapeutics (RDTCF) Overvalued in 2026?
Based on GuruFocus' analysis, Rapid Dose Therapeutics stock appears to be undervalued.
The current stock price of $0.08 is trading 73.3% below its estimated GF Value™ of $0.30.
GuruFocus considers Rapid Dose Therapeutics to be Possible Value Trap.
Key valuation signals for RDTCF:
Market Cap: $10.95 Mil
GF Value™: $0.30 vs. price of $0.08 (73.3% below fair value)
Industry Position: 91% below the Biotechnology median (#1193 of 1420)
No single metric tells the full story. See the RDTCF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.
27GF Score
Get the complete analysis for RDTCF
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RDTCF has been successfully added to your 
